Membrane interaction of disease-related dynorphin A variants

Biochemistry

Volumn 52, Issue 24, 2013, Pages 4157-4167

  Björnerås, Johannes ^a   Gräslund, Astrid ^a   Mäler, Lena ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GENE MUTATIONS; ISOTROPIC SOLUTIONS; MEMBRANE INTERACTIONS; NEGATIVELY CHARGED; NEURODEGENERATIVE DISORDERS; NUCLEAR MAGNETIC RESONANCE(NMR); PARAMAGNETIC PROBES; PARAMAGNETIC SPINS;

AMINO ACIDS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARAMAGNETISM;

PEPTIDES;

BUFFER; DYNORPHIN A;

ALPHA HELIX; ARTICLE; CARBOXY TERMINAL SEQUENCE; CIRCULAR DICHROISM; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; ELECTRON SPIN RESONANCE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

CELL MEMBRANE; CIRCULAR DICHROISM; DIFFUSION; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DYNORPHINS; HUMANS; LIPID BILAYERS; MAGNETIC RESONANCE SPECTROSCOPY; MICELLES; MUTATION; PEPTIDES; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; PHOSPHOLIPID ETHERS; PROTEIN CONFORMATION; SOLVENTS; THERMODYNAMICS; WATER;

EID: 84879217931     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi4004205     Document Type: Article

References (75)

1. Teschemacher, H., Opheim, K. E., Cox, B. M., and Goldstein, A. (1975) A peptide-like substance from pituitary that acts like morphine. I. Isolation Life Sci. 16, 1771-1775
2. Goldstein, A., Tachibana, S., Lowney, L., Hunkapiller, M., and Hood, L. (1979) Dynorphin-(1-13), an extraordinarily potent opioid peptide Proc. Natl. Acad. Sci. U.S.A. 76, 6666-6670
3. Chavkin, C. and Goldstein, A. (1981) Demonstration of a specific dynorphin receptor in guinea pig ileum myenteric plexus Nature 291, 591-593
4. Chavkin, C. and Goldstein, A. (1981) Specific receptor for the opioid peptide dynorphin: Structure-activity relationships Proc. Natl. Acad. Sci. U.S.A. 78, 6543-6547
5. Chavkin, C., James, I. F., and Goldstein, A. (1982) Dynorphin is a specific endogenous ligand of the kappa opioid receptor Science 215, 413-415
6. Oka, T., Negishi, K., Suda, M., Sawa, A., Fujino, M., and Wakimasu, M. (1982) Evidence that dynorphin-(1-13) acts as an agonist on opioid κ-receptors Eur. J. Pharmacol. 77, 137-141
7. Kakidani, H., Furutani, Y., Takahashi, H., Noda, M., Morimoto, Y., Hirose, T., Asai, M., Inayama, S., Nakanishi, S., and Numa, S. (1982) Cloning and sequence analysis of cDNA for porcine β-neo-endorphin/dynorphin precursor Nature 298, 245-249
8. Bakalkin, G. Y., Rakhmaninova, A. B., Akparov, V. K., Volodin, A. A., Ovchinnikov, V. V., and Sarkisyan, R. A. (1991) Amino acid sequence pattern in the regulatory peptides Int. J. Pept. Protein Res. 38, 505-510
9. Wen, H. L., Mehal, Z. D., Ong, B. H., and Ho, W. K. (1987) Treatment of pain in cancer patients by intrathecal administration of dynorphin Peptides 8, 191-193
10. Wen, H. L., Mehal, Z. D., Ong, B. H., Ho, W. K. K., and Wen, D. Y. K. (1985) Intrathecal administration of β-endorphin and dynorphin-(1-13) for the treatment of intractable pain Life Sci. 37, 1213-1220
11. Bruchas, M. R., Land, B. B., and Chavkin, C. (2010) The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors Brain Res. 1314, 44-55
12. Bruijnzeel, A. W. (2009) Kappa-opioid receptor signaling and brain reward function Brain Res. Rev. 62, 127-146
13. Tejeda, H. A., Shippenberg, T. S., and Henriksson, R. (2012) The dynorphin/κ-opioid receptor system and its role in psychiatric disorders Cell. Mol. Life Sci. 69, 857-896
14. Bakshi, R. and Faden, A. I. (1990) Competitive and non-competitive NMDA antagonists limit dynorphin A-induced rat hindlimb paralysis Brain Res. 507, 1-5
15. Walker, J. (1982) Nonopiate effects of dynorphin and des-tyr-dynorphin Science 218, 1136-1138
16. Tan-No, K., Cebers, G., Yakovleva, T., Goh, B. H., Gileva, I., Reznikov, K., Aguilar-Santelises, M., Hauser, K. F., Terenius, L., and Bakalkin, G. (2001) Cytotoxic effects of dynorphins through nonopioid intracellular mechanisms Exp. Cell Res. 269, 54-63
17. Marinova, Z., Vukojevic, V., Surcheva, S., Yakovleva, T., Cebers, G., Pasikova, N., Usynin, I., Hugonin, L., Fang, W., Hallberg, M., Hirschberg, D., Bergman, T., Langel, U., Hauser, K. F., Pramanik, A., Aldrich, J. V., Gräslund, A., Terenius, L., and Bakalkin, G. (2005) Translocation of dynorphin neuropeptides across the plasma membrane. A putative mechanism of signal transmission J. Biol. Chem. 280, 26360-26370
18. Hugonin, L., Vukojević, V., Bakalkin, G., and Gräslund, A. (2006) Membrane leakage induced by dynorphins FEBS Lett. 580, 3201-3205
19. 31P NMR spectroscopy Biochim. Biophys. Acta 1158, 34-44
20. Naqvi, T., Haq, W., and Mathur, K. B. (1998) Structure-activity relationship studies of dynorphin A and related peptides Peptides 19, 1277-1292
21. Lung, F. T., Chen, C., and Liu, J. (2005) Development of highly potent and selective dynorphin A analogues as new medicines J. Pept. Res. 66, 263-276
22. Arttamangkul, S., Ishmael, J. E., Murray, T. F., Grandy, D. K., DeLander, G. E., Kieffer, B. L., and Aldrich, J. V. (1997) Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the "address" sequence J. Med. Chem. 40, 1211-1218
23. Arttamangkul, S., Murray, T. F., DeLander, G. E., and Aldrich, J. V. (1995) Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 1. Conformational constraint in the "message" sequence J. Med. Chem. 38, 2410-2417
24. Choi, H., Murray, T. F., DeLander, G. E., Caldwell, V., and Aldrich, J. V. (1992) N-Terminal alkylated derivatives of [ d -Pro10]dynorphin A-(1-11) are highly selective for κ-opioid receptors J. Med. Chem. 35, 4638-4639
25. Choi, H., Murray, T. F., DeLander, G. E., Schmidt, W. K., and Aldrich, J. V. (1997) Synthesis and opioid activity of [ d -Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution J. Med. Chem. 40, 2733-2739
26. Fang, W., Cui, Y., Murray, T. F., and Aldrich, J. V. (2009) Design, synthesis, and pharmacological activities of dynorphin A analogues cyclized by ring-closing metathesis J. Med. Chem. 52, 5619-5625
27. Gairin, J. E., Mazarguil, H., Alvinerie, P., Saint-Pierre, S., Meunier, J. C., and Cros, J. (1986) Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties J. Med. Chem. 29, 1913-1917
28. Lapalu, S., Moisand, C., Mazarguil, H., Cambois, G., Mollereau, C., and Meunier, J. C. (1997) Comparison of the structure-activity relationships of nociceptin and dynorphin A using chimeric peptides FEBS Lett. 417, 333-336
29. Lemaire, S., Lafrance, L., and Dumont, M. (1986) Synthesis and biological activity of dynorphin-(1-13) and analogs substituted in positions 8 and 10 Int. J. Pept. Protein Res. 27, 300-305
30. Lung, F. D., Collins, N., Stropova, D., Davis, P., Yamamura, H. I., Porreca, F., and Hruby, V. J. (1996) Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphin A(1-11)-NH2 J. Med. Chem. 39, 1136-1141
31. Meyer, J. P., Collins, N., Lung, F. D., Davis, P., Zalewska, T., Porreca, F., Yamamura, H. I., and Hruby, V. J. (1994) Design, synthesis, and biological properties of highly potent cyclic dynorphin A analogues. Analogues cyclized between positions 5 and 11 J. Med. Chem. 37, 3910-3917
32. Patkar, K. A., Murray, T. F., and Aldrich, J. V. (2009) The effects of C-terminal modifications on the opioid activity of [N-BenzylTyr1]dynorphin A-(1-11) analogues J. Med. Chem. 52, 6814-6821
33. Snyder, K. R., Story, S. C., Heidt, M. E., Murray, T. F., DeLander, G. E., and Aldrich, J. V. (1992) Effect of modification of the basic residues of dynorphin A-(1-13) amide on kappa opioid receptor selectivity and opioid activity J. Med. Chem. 35, 4330-4333
34. Vig, B. S., Murray, T. F., and Aldrich, J. V. (2004) Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3 J. Med. Chem. 47, 446-455
35. 2 that lacks the basic N-terminus J. Med. Chem. 46, 1279-1282
36. Yoshino, H., Nakazawa, T., Arakawa, Y., Kaneko, T., Tsuchiya, Y., Matsunaga, M., Araki, S., Ikeda, M., Yamatsu, K., and Tachibana, S. (1990) Synthesis and structure-activity relationships of dynorphin A-(1-8) amide analogues J. Med. Chem. 33, 206-212
37. Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G. W., Vardy, E., Liu, W., Thompson, A. A., Huang, X., Carroll, F. I., Mascarella, S. W., Westkaemper, R. B., Mosier, P. D., Roth, B. L., Cherezov, V., and Stevens, R. C. (2012) Structure of the human κ-opioid receptor in complex with JDTic Nature 485, 327-332
38. Bakalkin, G., Watanabe, H., Jezierska, J., Depoorter, C., Verschuuren-Bemelmans, C., Bazov, I., Artemenko, K. A., Yakovleva, T., Dooijes, D., and Van de Warrenburg, B. P. C. (2010) Prodynorphin mutations cause the neurodegenerative disorder spinocerebellar ataxia type 23 Am. J. Hum. Genet. 87, 593-603
39. Jezierska, J., Stevanin, G., Watanabe, H., Fokkens, M. R., Zagnoli, F., Kok, J., Goas, J., Bertrand, P., Robin, C., Brice, A., Bakalkin, G., Durr, A., and Verbeek, D. S. (2013) Identification and characterization of novel PDYN mutations in dominant cerebellar ataxia cases J. Neurol. DOI: 10.1007/s00415-013-6882-6
40. Madani, F., Taqi, M. M., Wärmländer, S. K. T. S., Verbeek, D. S., Bakalkin, G., and Gräslund, A. (2011) Perturbations of model membranes induced by pathogenic dynorphin A mutants causing neurodegeneration in human brain Biochem. Biophys. Res. Commun. 411, 111-114
41. Sargent, D. F. and Schwyzer, R. (1986) Membrane lipid phase as catalyst for peptide-receptor interactions Proc. Natl. Acad. Sci. U.S.A. 83, 5774-5778
42. Alford, D. R., Renugopalakrishnan, V., and Duzgunes, N. (1996) Dynorphin-phospholipid membrane interactions: Role of phospholipid head-group and cholesterol Int. J. Pept. Protein Res. 47, 84-90
43. Hugonin, L., Barth, A., Gräslund, A., and Perálvarez- Marín, A. (2008) Secondary structure transitions and aggregation induced in dynorphin neuropeptides by the detergent sodium dodecyl sulfate Biochim. Biophys. Acta 1778, 2580-2587
44. Lind, J., Gräslund, A., and Mäler, L. (2006) Membrane interactions of dynorphins Biochemistry 45, 15931-15940
45. Schwyzer, R. (1986) Estimated conformation, orientation, and accumulation of dynorphin A-(1-13)-tridecapeptide on the surface of neutral lipid membranes Biochemistry 25, 4281-4286
46. Glover, K. J., Whiles, J. A., Wu, G., jun Yu, N., Deems, R., Struppe, J. O., Stark, R. E., Komives, E. A., and Vold, R. R. (2001) Structural evaluation of phospholipid bicelles for solution-state studies of membrane-associated biomolecules Biophys. J. 81, 2163-2171
47. Vold, R., Prosser, R. S., and Deese, A. (1997) Isotropic solutions of phospholipid bicelles: A new membrane mimetic for high-resolution NMR studies of polypeptides J. Biomol. NMR 9, 329-335
48. Svennerholm, L. (1968) Distribution and fatty acid composition of phosphoglycerides in normal human brain J. Lipid Res. 9, 570-579
49. Mäler, L. and Gräslund, A. (2011) NMR Studies of Three-Dimensional Structure and Positioning of CPPs in Membrane Model Systems Methods Mol. Biol. 683, 57-67
50. Louis-Jeune, C., Andrade-Navarro, M., and Perez-Iratxeta, C. (2012) Prediction of protein secondary structure from circular dichroism using theoretically derived spectra Proteins 80, 374-381
51. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A. (1995) NMRPipe: A multidimensional spectral processing system based on UNIX pipes J. Biomol. NMR 6, 277-293
52. Goddard, T. D. and Kneller, D. G. (2006) Sparky 3, University of California, San Francisco.
53. Vogel, A., Scheidt, H. A., and Huster, D. (2003) The distribution of lipid attached spin probes in bilayers: Application to membrane protein topology Biophys. J. 85, 1691-1701
54. Callaghan, P. T., Komlosh, M. E., and Nyden, M. (1998) High magnetic field gradient PGSE NMR in the presence of a large polarizing field J. Magn. Reson. 133, 177-182
55. Stejskal, E. O. and Tanner, J. E. (1965) Spin diffusion measurements: Spin echoes in the presence of a time-dependent field gradient J. Chem. Phys. 42, 288-288
56. von Meerwall, E. and Kamat, M. (1989) Effect of residual field gradients on pulsed-gradient NMR diffusion measurements J. Magn. Reson. 83, 309-323
57. Longsworth, L. (1960) The mutual diffusion of light and heavy water J. Phys. Chem. 64, 1914-1917
58. van Dam, L., Karlsson, G., and Edwards, K. (2004) Direct observation and characterization of DMPC/DHPC aggregates under conditions relevant for biological solution NMR Biochim. Biophys. Acta 1664, 241-256
59. Triba, M. N., Warschawski, D. E., and Devaux, P. F. (2005) Reinvestigation by phosphorus NMR of lipid distribution in bicelles Biophys. J. 88, 1887-1901
60. Chou, J. J., Kaufman, J. D., Stahl, S. J., Wingfield, P. T., and Bax, A. (2002) Micelle-induced curvature in a water-insoluble HIV-1 Env peptide revealed by NMR dipolar coupling measurement in a stretched polyacrylamide gel J. Am. Chem. Soc. 124, 2450-2451
61. Andersson, A. and Mäler, L. (2005) Magnetic resonance investigations of lipid motion in isotropic bicelles Langmuir 21, 7702-7709
62. 15N random coil NMR chemical shifts of the common amino acids. I. Investigations of nearest-neighbor effects J. Biomol. NMR 5, 67-81
63. Marsh, J. A., Singh, V. K., Jia, Z., and Forman-Kay, J. (2006) Sensitivity of secondary structure propensities to sequence differences between α- and γ-synuclein: Implications for fibrillation Protein Sci. 15, 2795-2804
64. Perczel, A., Lengyel, I., Mantsch, H. H., and Fasman, G. D. (1993) Analysis of hydrogen bonds in peptides, based on the hydration affinity of amides J. Mol. Struct. 297, 115-126
65. Zhou, N. E., Zhu, B. Y., Sykes, B. D., and Hodges, R. S. (1992) Relationship between amide proton chemical shifts and hydrogen bonding in amphipathic α-helical peptides J. Am. Chem. Soc. 114, 4320-4326
66. Sankararamakrishnan, R. and Weinstein, H. (2000) Molecular dynamics simulations predict a tilted orientation for the helical region of dynorphin A(1-17) in dimyristoylphosphatidylcholine bilayers Biophys. J. 79, 2331-2344
67. de Planque, M. R., Kruijtzer, J. A., Liskamp, R. M., Marsh, D., Greathouse, D. V., Koeppe, R. E., II, de Kruijff, B., and Killian, J. A. (1999) Different membrane anchoring positions of tryptophan and lysine in synthetic transmembrane α-helical peptides J. Biol. Chem. 274, 20839-20846
68. Killian, J. A. and von Heijne, G. (2000) How proteins adapt to a membrane-water interface Trends Biochem. Sci. 25, 429-434
69. 13C solid-state NMR J. Mol. Struct. 749, 13-19
70. 1H NMR investigation of the conformation of methionine-enkephalin in fast-tumbling bicelles Biophys. J. 86, 1587-1600
71. Wimley, W. C. and White, S. H. (1996) Experimentally determined hydrophobicity scale for proteins at membrane interfaces Nat. Struct. Biol. 3, 842-848
72. Janecka, A., Fichna, J., and Janecki, T. (2004) Opioid receptors and their ligands Curr. Top. Med. Chem. 4, 1-17
73. Turcotte, A., Lalonde, J., St-Pierre, S., and Lemaire, S. (1984) Dynorphin-(1-13). I. Structure-function relationships of Ala-containing analogs Int. J. Pept. Protein Res. 23, 361-367
74. Kawasaki, A. M., Knapp, R. J., Walton, A., Wire, W. S., Zalewska, T., Yamamura, H. I., Porreca, F., Burks, T. F., and Hruby, V. J. (1993) Syntheses, opioid binding affinities, and potencies of dynorphin A analogues substituted in positions, 1, 6, 7, 8 and 10 Int. J. Pept. Protein Res. 42, 411-419
75. Watanabe, H., Mizoguchi, H., Verbeek, D. S., Kuzmin, A., Nyberg, F., Krishtal, O., Sakurada, S., and Bakalkin, G. (2012) Non-opioid nociceptive activity of human dynorphin mutants that cause neurodegenerative disorder spinocerebellar ataxia type 23 Peptides 35, 306-310